Moleculin Biotech Inc

This management proposal requests shareholder approval to materially increase the pool of shares available under Moleculin’s 2024 Equity Incentive Plan from the remaining available balance (~14,105) and prior authorization (280,010) to an aggregate authorization that would allow issuance of 3,875,999 new shares (total request 4,141,894). Management frames this as necessary to continue using equity as a core part of compensation to attract, retain and motivate employees and directors while conserving cash for clinical programs; they note the increase would represent roughly 19.9% of outstanding shares (21.3% when including outstanding awards). The plan includes investor-friendly governance features — independent administration by the compensation committee, no evergreen provision, a prohibition on repricing without shareholder approval, dividend limitations, exercise-price and term limits, and caps on non-employee director compensation — which the Board highlights to mitigate dilution and governance concerns. Approval would provide the Compensation Committee flexibility to grant stock options, RSUs, SARs and other awards used to align personnel incentives with shareholder value and to implement planned grants tied to the 2025/2026 compensation year. The Board relied on its independent compensation consultant when assessing the requested size and concluded the proposed capitalization sits within the expected range for similarly capitalized biotech peers. The principal downside for shareholders is dilution and the potential decrease in per-share economic interest; management discloses the expected dilution metrics and that shares withheld to satisfy exercises or taxes will not replenish the pool. Given the company’s clinical-stage profile and stated intention to conserve cash, equity-based compensation is a predictable strategy, but shareholders should weigh the trade-off between dilution and management’s retention/incentive rationale. The Board’s recommendation and the plan’s structural protections reduce certain governance risks, but the proposal remains a material capitalization action with significant potential long-term dilution that sophisticated investors should evaluate in the context of the company’s financing runway, pipeline milestones and historical equity grant practices.

This advisory 'say-on-pay' proposal asks shareholders to approve, on a non-binding basis, the compensation paid to Moleculin’s named executive officers as disclosed in the proxy. Management frames pay as intended to align executives with long-term shareholder value through a mix of cash, bonuses subject to performance goals, and significant equity grants; the company also notes recent shareholder feedback favoring a greater proportion of equity compensation. The company’s 2025 advisory vote previously received approximately 63% support, which management characterized as below expectations and prompted outreach to institutional holders; management reports limited engagement responses but states it has adjusted its practices (e.g., relying more on equity and freezing cash increases until financing). As an advisory vote, the result is non-binding, but the Board and Compensation Committee commit to reviewing results and considering them in future compensation decisions. From a governance perspective, the proposal provides a forum for shareholders to signal approval or concern about pay-for-performance alignment and the balance between cash and equity; significant opposition would likely prompt further engagement or program changes. The Board’s recommendation to vote FOR indicates management’s confidence in its compensation design and disclosure; sophisticated investors should weigh historical pay outcomes, recent say-on-pay results, the company’s cash constraints, and the role of the 2024 Plan (if increased per Proposal 3) in supporting future equity awards when evaluating the governance implications of their vote.

This proposal requests that shareholders eliminate a two-thirds supermajority voting threshold in Article 8 of the charter and permit future charter amendments to be approved by a simple majority consistent with the Delaware General Corporation Law. Management argues this aligns the company with common governance best practices and stockholder expectations, reducing entrenched protections that can impede ordinary corporate housekeeping and governance updates. The existing supermajority covered a broad set of protections — director selection and terms, indemnification and limitation of liability, the ability to amend charter provisions, the company’s choice to be governed by DGCL Section 203, and the ability of stockholders to act by written consent — all areas investors typically scrutinize for balance between managerial stability and shareholder rights. Removing the supermajority lowers the barrier to future charter amendments but could make certain anti-takeover protections easier to change; however, the board frames the change as modernization rather than an attempt to facilitate specific governance transactions. The vote requirement to approve this amendment in the current meeting is itself a high threshold (two-thirds), and management’s recommendation to support the change signals Board confidence that majority approval is an appropriate standard going forward. Investors should consider the trade-offs: improved flexibility and alignment with standard governance norms versus the potential for easier future charter amendments that could be used opportunistically if not accompanied by other shareholder protections. Overall, removing supermajority provisions is generally viewed favorably by institutional investors seeking neutral governance frameworks, but sophisticated investors will evaluate this in the context of the company’s broader governance record and any related entrenchment concerns.

The Board seeks shareholder authorization to amend the charter so it can, if it chooses within one year, implement a reverse stock split at a ratio between 1-for-2 and 1-for-20. The principal rationale is pragmatic: the company’s closing price on the record date (~$0.572) is below Nasdaq’s $1.00 minimum bid-price criterion; a reverse split could increase the per-share price and reduce delisting risk. Management emphasizes flexibility, giving the Board discretion to select the specific ratio (within the approved range) based on market conditions and to decline to implement the split if not in shareholders’ interests. The company discloses prior reverse splits (1-for-15 in March 2024 and 1-for-25 in December 2025) that produced temporary increases but did not maintain long-term price performance, which is an important historical datapoint that tempers expectations. Potential downsides include no guarantee of sustained price improvement, possible decrease in market capitalization, reduced liquidity due to fewer outstanding shares, increased number of authorized-but-unissued shares (which could be dilutive if issued) and the treatment of fractional shares via cash payments. The board’s authority to select the ratio post-approval increases agility but also places a significant discretionary decision in management’s hands; sophisticated investors should monitor any subsequent decision closely and weigh the reverse split’s potential listing benefits against its possible market and dilution consequences. Overall, the proposal is defensive and listing-preservation oriented rather than value-creating per se; its effectiveness depends on follow-on market reception, continued operational progress, and subsequent capital actions by the company.

This proposal asks shareholders to grant the proxy holders authority to adjourn the meeting to solicit additional proxies if insufficient votes exist to approve proposals at the scheduled meeting. Procedurally this is a common board-requested authorization that provides flexibility to avoid holding a separate meeting and permits the company to continue solicitation efforts, potentially changing outcomes through additional outreach. The ability to adjourn without giving separate notice (if under 30 days and no new record date) makes it administratively efficient; however, it also allows management to delay final votes and continue persuasion efforts, which could be material if votes appear close. The proposal requires a simple majority of votes cast (excluding broker non-votes and abstentions) and the Board recommends FOR. From a governance lens, investors often approve such adjournment authorization for pragmatic reasons but may scrutinize subsequent use if it appears intended to circumvent the will of shareholders rather than to obtain broader participation. Sophisticated investors should note this gives management tactical leverage near the meeting date and should consider whether assurance on solicitation practices and transparency around follow-up outreach is sufficient when evaluating the company’s governance posture.